Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology

Understanding the Connection Between HTLV-1 and ATLL

At a Glance

Adult T-cell leukemia/lymphoma (ATLL) is a rare blood cancer caused by the HTLV-1 virus. The virus has a 20 to 50-year latency period, meaning most people are diagnosed decades after infection. Only 3 to 5 percent of people who carry HTLV-1 will ever develop ATLL.

Finding out that a virus you may have lived with for decades has caused a serious illness can be overwhelming. It is completely normal to feel shocked, confused, or even a sense of betrayal by your own body. Many people with Adult T-cell leukemia/lymphoma (ATLL) never knew they carried the virus until their diagnosis [1]. Understanding the connection between the virus and the disease is a vital first step in navigating your care.

What is ATLL?

Adult T-cell leukemia/lymphoma (ATLL) is a rare and complex cancer of the T-cells, which are a type of white blood cell that normally helps your immune system fight infections [2][3]. ATLL is unique because it is caused by the Human T-lymphotropic virus type 1 (HTLV-1) [4][5].

While millions of people worldwide carry HTLV-1, the vast majority (about 95%) will never develop ATLL [6][7]. For the small percentage (roughly 3–5%) who do, the disease usually appears only after a very long latency period—often 20 to 50 years after the initial infection [8][9].

The HTLV-1 Connection: A Decades-Long Process

The virus does not cause cancer overnight. Instead, it plays a “long game” inside your body:

  • Viral Persistence: After infection, the virus integrates its genetic material into your T-cells [4].
  • Specific Proteins: The virus produces specific proteins that act like “on switches,” telling the T-cells to keep dividing and survive longer than they should [10][11].
  • Accumulated Changes: Over several decades, these constantly dividing cells can accumulate genetic mistakes (mutations) [9][12]. Eventually, one of these cells may become cancerous, leading to ATLL.

Transmission: Protecting Your Family

Learning you have HTLV-1 immediately raises questions about your loved ones. The virus is not spread through casual contact, hugging, or sharing utensils. It is transmitted in specific ways:

  • Mother to Child: Primarily through prolonged breastfeeding (this is the most common route for those who develop ATLL decades later) [8].
  • Sexual Contact: Unprotected sex is a transmission route. You should use barrier methods (like condoms) to protect your partner [7].
  • Blood Exposure: Sharing needles or receiving infected blood transfusions (though blood supplies in many countries are now screened) can spread the virus [4].

Next Steps for Your Family: You cannot donate blood, organs, or tissue. If you have a partner or children, you should discuss HTLV-1 testing with your doctor to determine if they should be screened [6].

Why You May Not Have Heard of It

ATLL is geographically concentrated. It is most common in regions where the HTLV-1 virus is more prevalent:

  • Japan: Particularly the southwestern regions [8][2].
  • The Caribbean Basin: Including Jamaica and Haiti [8].
  • South America and Africa: Specifically parts of Brazil, Peru, and Central Africa [13][14].

In the United States, ATLL is very rare, though the incidence is slightly higher in areas with large immigrant populations from the regions mentioned above [15][16]. Because of this rarity, many local doctors may have never seen a case. This makes it essential to seek care at a major cancer center with experience in T-cell lymphomas.

Stabilizing Facts for the Newly Diagnosed

When you are first diagnosed, it helps to focus on what is known and established:

  1. Diagnosis is Definitive: Doctors use specific tests to confirm ATLL, including looking for HTLV-1 antibodies in the blood and identifying “flower cells” (uniquely shaped T-cells) under a microscope [15][17]. Knowing exactly what you are fighting is the first step toward a plan.
  2. Specialized Treatments Exist: While ATLL is aggressive, there are dedicated treatments. These include antiviral therapies, chemotherapy, and newer targeted therapies like mogamulizumab [18][19].
  3. Potential for Cure: For many patients, an allogeneic hematopoietic stem cell transplant—using healthy stem cells from a donor—is considered a potentially curative option [20][21].

What Research is Still Exploring

While we understand the “how” of the virus, scientists are exploring:

  • Predicting Risk: Why do some people develop ATLL while 95% do not? Researchers are looking at the proviral load (the amount of virus in the blood) as a possible predictor [22].
  • New Targeted Therapies: Ongoing clinical trials are testing new drugs to see if they can provide longer remissions with fewer side effects [23][24].

Common questions in this guide

How does the HTLV-1 virus cause ATLL?
After infection, the HTLV-1 virus integrates its genetic material into your T-cells. It produces proteins that force these cells to divide rapidly, eventually allowing genetic mutations to build up and cause cancer decades later.
Can I spread HTLV-1 to my family through casual contact?
No, HTLV-1 is not spread through hugging, sharing utensils, or casual contact. It is transmitted only through prolonged breastfeeding, unprotected sex, and direct blood exposure such as sharing needles.
Should my family be tested for HTLV-1?
Because HTLV-1 can be transmitted sexually or from mother to child, you should discuss testing your partner and children with your doctor. To protect others, you must also refrain from donating blood, organs, or tissues.
What does an HTLV-1 proviral load test measure?
The proviral load test measures the amount of HTLV-1 virus present in your blood. Doctors and researchers use this measurement to help predict the risk of disease progression and determine the best monitoring strategy.
Can ATLL be cured?
While ATLL is an aggressive cancer, an allogeneic hematopoietic stem cell transplant—which replaces diseased bone marrow with healthy cells from a donor—is considered a potentially curative treatment for eligible patients.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my HTLV-1 status confirmed with a PCR test to determine my proviral load?
  2. 2.Should my partner or children be tested for HTLV-1, and what is the best way to arrange that?
  3. 3.Does our team consult with experts in high-incidence regions like Japan or the Caribbean?
  4. 4.What are the specific steps I need to take to ensure I don't transmit the virus to others?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Epidemiology of adult T-cell leukemia/lymphoma (ATL) in people living with HTLV-1: A 30-year study in Peru.

    Garrido-Pinzás G, Valenzuela B, González-Lagos E, et al.

    PLoS neglected tropical diseases 2026; (20(2)):e0014010 doi:10.1371/journal.pntd.0014010.

    PMID: 41729993
  2. 2

    Lymphomatous adult T cell leukaemia/lymphoma with anaplastic morphology in a country non-endemic for HTLV: a mimicker of anaplastic large cell lymphoma.

    Li CH, Chang ST, Wu HC, et al.

    Histopathology 2020; (77(4)):678-680 doi:10.1111/his.14173.

    PMID: 32510673
  3. 3

    KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

    Hurabielle C, Leboeuf C, Ram-Wolff C, et al.

    The British journal of dermatology 2018; (179(1)):197-199 doi:10.1111/bjd.16322.

    PMID: 29315492
  4. 4

    HTLV-1 bZIP factor: the key viral gene for pathogenesis.

    Matsuoka M, Mesnard JM

    Retrovirology 2020; (17(1)):2 doi:10.1186/s12977-020-0511-0.

    PMID: 31915026
  5. 5

    The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.

    Kgatle M, Mbambara S, Khoza L, et al.

    Frontiers in microbiology 2025; (16()):1602497 doi:10.3389/fmicb.2025.1602497.

    PMID: 40589575
  6. 6

    HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.

    Giam CZ, Semmes OJ

    Viruses 2016; (8(6)).

    PMID: 27322308
  7. 7

    Adult T cell leukaemia/lymphoma (ATL) in pregnancy: A UK case series.

    Motedayen Aval L, Boullier M, Lyall H, et al.

    EJHaem 2021; (2(1)):131-135 doi:10.1002/jha2.142.

    PMID: 35846087
  8. 8

    Peripheral lymphocytosis presenting as EBV/HTLV-1 co-infection adult T-cell leukemia.

    Kasinathan G, Sathar J

    Hematology, transfusion and cell therapy 2022; (44(2)):279-283 doi:10.1016/j.htct.2020.09.146.

    PMID: 33281112
  9. 9

    How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

    Bangham CR, Ratner L

    Current opinion in virology 2015; (14()):93-100.

    PMID: 26414684
  10. 10

    NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ.

    Fochi S, Ciminale V, Trabetti E, et al.

    Pathogens (Basel, Switzerland) 2019; (8(4)) doi:10.3390/pathogens8040290.

    PMID: 31835460
  11. 11

    Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies.

    Vasconez-Gonzalez J, Suárez-Sangucho IA, Acosta-Muñoz E, et al.

    Frontiers in cellular and infection microbiology 2025; (15()):1587802 doi:10.3389/fcimb.2025.1587802.

    PMID: 40895309
  12. 12

    Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma.

    Yoshida N, Yamada K, Ohshima K

    Cancer science 2021; (112(4)):1339-1347 doi:10.1111/cas.14849.

    PMID: 33576080
  13. 13

    Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.

    Malpica L, Enriquez DJ, Castro DA, et al.

    JCO global oncology 2021; (7()):1151-1166 doi:10.1200/GO.21.00084.

    PMID: 34270330
  14. 14

    Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma.

    Phillips AA

    Current opinion in virology 2023; (58()):101289 doi:10.1016/j.coviro.2022.101289.

    PMID: 36584476
  15. 15

    Human T-lymphotropic virus 1 associated with adult T-cell leukemia/lymphoma.

    James T, Fivenson D, Cotton J

    Cutis 2018; (102(1)):E4-E7.

    PMID: 30138509
  16. 16

    Incidence of adult T-cell leukemia/lymphoma in nonendemic areas.

    Yoshida N, Chihara D

    Current treatment options in oncology 2015; (16(2)):7 doi:10.1007/s11864-014-0321-5.

    PMID: 25762122
  17. 17

    Human T-cell Lymphotropic Virus Type 1 (HTLV-1)-Associated Adult T-cell Leukemia/Lymphoma in a Patient Previously Treated for Strongyloidiasis.

    Basharat A, Anwar MY, Sulh M, et al.

    Cureus 2023; (15(10)):e47283 doi:10.7759/cureus.47283.

    PMID: 38021878
  18. 18

    Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.

    Sekine M, Kubuki Y, Kameda T, et al.

    European journal of haematology 2017; (98(5)):501-507 doi:10.1111/ejh.12863.

    PMID: 28152225
  19. 19

    Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.

    Sugio T, Kato K, Aoki T, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; (22(9)):1608-1614 doi:10.1016/j.bbmt.2016.05.017.

    PMID: 27220263
  20. 20

    Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.

    López-Pereira P, Bazarbachi A, Marçais A, et al.

    Bone marrow transplantation 2026; (61(3)):341-346 doi:10.1038/s41409-025-02783-z.

    PMID: 41486188
  21. 21

    Resolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post-transplant cyclophosphamide in adult T-cell leukemia/lymphoma.

    Iioka F, Tanabe H, Honjo G, et al.

    Clinical case reports 2020; (8(8)):1553-1559 doi:10.1002/ccr3.2925.

    PMID: 32884794
  22. 22

    A comprehensive assessment using multiple factors based on HAS-Flow analysis predicts ATL development and progression.

    Nakamura H, Watanabe T, Sato A, et al.

    Scientific reports 2025; (15(1)):26618 doi:10.1038/s41598-025-10822-4.

    PMID: 40695942
  23. 23

    Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.

    Miyazaki T, Uno S, Fujimori H, Motegi Y

    International journal of hematology 2025; (121(1)):79-88 doi:10.1007/s12185-024-03864-3.

    PMID: 39570473
  24. 24

    Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.

    Zinzani PL, Izutsu K, Mehta-Shah N, et al.

    The Lancet. Oncology 2024; (25(12)):1602-1613 doi:10.1016/S1470-2045(24)00503-5.

    PMID: 39486433

This page explains the connection between the HTLV-1 virus and ATLL for educational purposes only. Always consult your oncologist or infectious disease specialist for medical advice, family testing, and treatment planning.

Get notified when new evidence is published on Adult T-cell leukemia/lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.